Biotech ARIAD empfohlen! - 500 Beiträge pro Seite

[pauer1]

Biotech Firma ARIAD (arbeitet mit Hoechst zusammen und befindet sich im BB Biotech Aktiendepot) wurde von GLOBAL BIOTECH INVESTING vor einer Woche empfohlen.

Sie haben angeblich etwas gegen Krebs. Wenn da etwas an Infor kommt dann explodiert die Aktie. 50 Euro Höchststand zurzeit 4,90 Euro.

[BrokerPK]

wie ich es schon immer prophezeit habe explodiert die Aktie nun förmlich!!

derzeit aktuell 6,95 Euro in Frankfurt!!
und das war erst der Anfang!!

[touchme]

Bin heute eingestiegen zu 6.80 - und schon geht sie wieder in den Keller. Gibt`s Gründe dafür?

[kurttilly]

Bin seit 29.10.01 in Ariad investiert, sprang gleich nach den News bei 5,50€ auf den Zug, der danach ersteinmal den Rückwärtsgang einlegte; bin eigentlich ganz optimistisch und warte nur auf eine neue Meldung von Ariad z.B. einer Kooperation ...... dann geht`s sicherlich aufwärts.

[Menglovator]

@ ALL :

Hat jemand mehr Firmendaten (Bruttorendite, Nettorendite,Eigenkapital u.a.) ??

Der Menglovator

[Menglovator]

@ ALL :

Hat jemand mehr Firmendaten (Bruttorendite, Nettorendite,Eigenkapital u.a.) ??

Der Menglovator

[BrokerPK]

stetig steigt die geilste Aktie der Welt!?!?
meint ihr Amgen könnte Ariad evtlübernehmen??
nach der< Immunex Übernahme war von weiteren Deals die Rede...
habt ihr eine Videotextseite ausfindig machen können mit dem Ariad-Kurs??
2002 wird eine mega-performance hingelegt,da bin ich mir sicher!!

[Mr.Oddset]

Versuchs mal auf Bayern 3 ab Seite 535.

[Mr.Oddset]

Versuchs mal auf Bayern 3 ab Seite 535.

[Mr.Oddset]

Und auf ZDF Seite 691 4/4 in US$.

[pauer1]

Bei 6€ Bodenbildung.

Was ist das nächste Ziel?

[BrokerPK]

danke Mr.Oddset!!

aein Ziel lässt sich bei dieser Aktie nicht definieren....da ist alles drin nach oben!!
absolut langfristige Anlage,weil die story stimmt!!

Gruss

[mr.gekko]

Bodenbildung bei ca. 5,10 $, schwankungsbreite 5,10 - 5,60 $, ein Ausbruch über 6$ würde meines erachtes höhere kurse nach sich ziehen, charttechnik, storry ist in ordnung, die zittrigen sind aus dem markt, billigere kurse wird es nicht mehr geben!
euer mr.gekko

[bulley]

wie gehts mit der aktie weiter?
gibt es gründe zu kaufen?

[pauer1]

6€ Bodenbildung.

=> kaufen

[pauer1]

Schaut Euch auch diesen Biotech Wert.
924887 PANGEO
Wurde auch empfohlen und beginnt steil
nach Norden zu wandern.

Noch ist es nicht zu spät.

[pauer1]

ARIAD deutlich unter 6€. Einkaufen !!!!

Das wird es in einer Woche nicht mehr zu haben sein.

ARIAD wird überall empfohlen.

[bulley]

O,O das wird nix mehr,abwarten ist angesagt
zuviel gewinnmitnahmen
alle raus,sonst asche weg

[mr.gekko]

da die 5,10 $ nicht gehalten haben, rutschte der kurs schlagartig nach unten, alle indikatoren stark negativ, die 4,50 $ ist die nächste hürde nach unten, ist schwer einzuschätzen, ob sie hält.
Der MACD ist immer noch stark im sinkflug.
tendenz abwarten
gruß eurer mr. gekko

[BrokerPK]

ich nutze diese verhältnissmässig niedrigen Kurse und kaufe nach!!
bin sicher in einem Jahr lächeln wir über diese Kurse!!
Ariad hat mehr verdient!!!
bis was definitives rauskommt ist eine Frage der Zeit!!

viel spass noch mit Ariad!!

[mr.gekko]

die frage ist, bei welchem kurs steigen wir wieder ein. macd immer noch stark negativ, es kann meiner ansicht nach noch weiter nach unten gehen, biotechbereich ist momentan in korrektur, deshalb......warten, aber nicht zu lange

euer mr.gekko

[reichinrente]

Hi , also ich glaube gestern das Bewegungstief erkannt zu haben. MACC stehen im Überverkauften Bereich. Daher habe ich bei 3,5 $ zugeschlagen und freue mich auf steigende Kurse. Kann zwar sein, das wir nochmal die 3$ anlupfen aber die Chancen auf höher Kurse sind ungleich grösser und den tiefsten Punkt erwischt man eh` nie.

RiR

[mr.gekko]

noch immer alles im negativen bereich, kann noch kein zeichen der erholung erkennen, meiner meinung sind jetzt noch tiefere kurse zu erwarten!!!!!!!!!!!!!
die 3,50 $ werden nicht lange halten
Begründung: MACD immer noch stark fallend,
Stochastik gibt auch noch kein zeichen, eindeutig fallend.....
Taktik: warten........

euer mr. gekko

[mr.gekko]

Stochastik hat gedreht und gibt ein erstes kaufsignal, am macd ist eine umkehr nach oben zu erkennen, allerdings noch kein kaufsignal, was aber meiner meinung nach nicht mehr lange auf sich warten läßt.

umsätze sind nicht schlecht und die marke von 3,50$ scheint doch zu halten, wir sehen in amerika auch wieder langsam höhere kurse zu teilweise 3,63.

bin mal eingstiegen, mal sehen, ob ich recht habe, die märkte scheinen auch wieder nach oben zu drehen, dass ist ein gutes zeichen.

vom top sind wir gut 80% entfernt, da war vor 3 wochen noch ca 6,5$, wir werden sicher wieder in diese richtung gehen.

leute sammelt langsam wieder ein, die charttechnik springt langsam wieder auf grün!!!!!!

euer mr.gekko

[BrokerPK]

kann dem guten Mr.Gekko da nur zustimmen!!

in 2 Wochen gibts ja schließlich auch News;$$$$))!!!....

[mr.gekko]

nach der stochstik ist noch gut platz nach oben, der macd gibt ein kaufsignal!!!!!!!!!!
wer noch nicht eingestiegen ist, sollte dies meiner meinung nach jetzt tun, wir haben ein 80 % Potential vor uns liegen (kurzfristig)!!!!!!
Der 13 % Sprung gestern in amerika ist meiner meinung nach nicht auf news begründet, nur technische reaktion, da macd ein kaufsignal gegeben hat.

Aber::::::::

Es gibt bald Zahlen, wer weiß, vielleicht weiß irgendjemand mehr und deckt sich schon im vorfeld mit ariad aktien ein. Der Umsatz liegt bei 200.000 zumindest sehr gut!!!!!!!!

Bin gespannt wie es weitergeht

Euer mr.gekko

[Champagne]

Wann kommen denn die Zahlen genau?

Termin???

Was ist eigentlich mit den 3 Millionen Aktien die Ariad verkaufen will???

Die haben doch gar keinen Grund dazu!

Angeblich verfügen die doch über genügend Barreserven (ca. 48 Mill. Dollar).

Wer weiß was?

Mr.Gekko vielleicht!?

MfG Champagne

[gholzbauer]

Hornblower Fischer BioStocks Daily 05.02.02
( Thread: Hornblower Fischer BioStocks Daily 05.02.02 )

...
Gestern präsentierte sich mit Ariad Pharmaceuticals (ARIA; 895301) ein Small-Cap Biotechunternehmen (~120 Mio. USD Marktkapitalisierung) im Haus. Wir raten, den Wert zu verkaufen: Mit einer Cash-Position von 47 Mio. USD bei jährlichen Ausgaben von etwa 20 Mio. USD und nicht erwähnenswerten Umsätzen erscheint es uns sehr zweifelhaft (und für Investoren sehr risikobehaftet), dass Ariad seine insgesamt fünf Wirkstoffkandidaten in der klinischen Entwicklung zielstrebig und erfolgreich bis zur Phase III/Marktzulassung forcieren kann. Ariad fokussiert sich auf small molecule drugs gegen Krebs und hämatologische Indikationen, wobei man erst ein Präparat in der Phase II hat und der Rest sich in der Vorklinik befindet. Zukünftig soll jedes Quartal ein Wirkstoff die nächste Stufe in seiner klinischen Entwicklung erreichen. Skeptisch stimmt uns auch die Strategie, bis zum Ende der Phase II alle Projekte im Alleingang durchführen zu wollen. Renommierte und finanzstarke Kooperationspartner, die die Technologie und Expertise von Ariad validieren, fehlen und sollen frühestens mit dem Eintritt der Kandidaten in die Phase III präsentiert werden. Mit einer limitierten Cash-Position, mit einer breiten aber sehr jungen Pipeline und den fehlenden strategischen Partnern ist von einem Investment in Ariad abzuraten. UNDERPERFORM
...

[mr.gekko]

wie wahr, wie wahr, es ist wirklich ein sehr junges unternehmen, das ist klar, aber wir gehen ja davon aus, dass schließlich ein paar produkte die marktreife erhalten.
ich glaube eher, das da jemand billig einkaufen will. in amerika hält sich der kurs gut bei 3.70 $.
Indikatoren sind nach wie vor auf grün. allerdings ist das marktumfeld echt schlecht?!
Ich bleibe long

euer mr.gekko

PS. schaut euch doch die analysten an, klassisches beispiel ist die telekom, noch von der deutschen bank empfohlen und dann haben sie selber einen tag später telekom verkauft. die wissen doch auch nicht mehr!!!!!!!1

[reichinrente]

@Gekko,
sehe ich genauso. Analysten-tipps taugen z.Zt. eher als Kontraindikator. Die News der Hornbläser sind zwar recht annehmbar aber gerade den Empfehlungen haben sie bisher besonders schlecht dagestanden (Stand auch im Handelsblatt vor ein paar Wochen). Ariad ist schlichtweg eine kleine noch relativ ungecoverte Biotech-Schmiede mit 120 mio MK, bei 40% Cash und einer breiten jungen Produktpalette mit den üblichen Risiken aber auch mit äußerst überdurchschnittlichen Chancen. Chart-technisch sieht es auch gut aus, die Unterstützung bei 3,5 $ wurde mehrfach verteidigt - bei schlechtem Umfeld. Ich bleibe drin.

RiR

[reichinrente]

Die 3,5 wurden trotz des miesen Umfelds wieder verteidigt.
Das bedeutet Rating: Outperfrom !

RiR

[reichinrente]

ARIA heute schon auf 4,11 $ ! Bleibe dabei!

RiR

[pauer1]

Merrill Lynch hatt gesagt:"So günstig bekommt man Biotechwerte nie wieder ..."

Und ARIAD zählt dazu.

[haggibaer]

Hallo Leute

Bitte Info wann die Zahlen kommen.
Wann sollte man zu welchem Kuzrs einsteigen ?

Vielen Dank

HARALD

[haggibaer]

Irgendwelche Infos für mich !! ??

Haggi

[haggibaer]

Hallo !!!!

Irgendwelche Info ??????????

haggi

[JohnMcLee]

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=aria&…

[haggibaer]

Sorry aber diese Adresse bringt bei mir eine Fehlermeldung

Was steht dort ?

Vielen Dank

haggi

[JohnMcLee]

20-Feb-2002 ARIAD Reports 2001 Q4 and Total Year Results

http://www.ariad.com/news/newsrel.html

[pauer1]

ARIAD habe ich schon lange. Irgendwie will sie nich nach oben. Gute Firma aber .....

Mit PANGEO (924887) habe ich bessere Erfahrungen gemacht. In die ist erst am Anfang...

[haggibaer]

Also jetzt sind die Zahlen raus - und was tut sich ??

An der 5 Euro Linie ist sie ja jetzt bereits einige Male abgeprallt
kommt jetzt irgendwann der Durchbruch ( Bullen Flagge ) ?

Bitte Eure Meinung

haggi

[Mister NO]

wo sind die zahlen und wie waren die???????

[haggibaer]

Die Zahlen findest Du hier :

20-Feb-2002 ARIAD Reports 2001 Q4 and Total Year Results

http://www.ariad.com/news/newsrel.html

[haggibaer]

Hab den Einstieg wieder verpasst - Was glaubt Ihr
wohin geht`s jetzt ?

haggi

[reichinrente]

Hi Haggi,
ich halte ARIAD (Einstieg 3,5 $) und wollte die Position letzte Woche eigentlich glattstellen , habe aber anders entschieden. Hier meine Gründe:
1. Es hat sich in den letzten Tagen ein schöner Aufwärtstrend ausgebildet mit zunehmender Dynamik.
2. Guter News-Flow läßt das gesamte Bio-Segment steigen.
3. In den letzten beiden Handelstagen sind die Bio-Schwergewichte gestiegen - Fonds gehen hier zuerst rein. Erfahrungsgemäß holen steigen danach die Small/Mid-caps. Hier wird Ariad nochmal stärker zulegen können.

Daher bleibe ich erstmal drin.
Gruß

BiR

[thebull 2]

Mit ARIAD PHARMA geben wir Ihnen heute
erneut eine ganz, ganz heisse
Top-Empfehl-ung an die Hand! Wie die
Gesellschaft kürzlich mitgeteilt hat, hat das
Unternehmen eine Reihe von hochwirksamen
Verbindungen zur Krebs-bekämpfung entdeckt.
Die gefundenen Moleküle haben in Versuchen
das Wachstum von Brust-, Prostata-, Nieren-,
Lugen- und Knochnkrebs gestoppt, indem sie die
für das Zellwachstum
und Metastastenbildung benötigte Informations-
übertragung erfolgreich unterbrochen haben.
Hier zeichnet sich nach Informationen unserer
US-amerikanischen Analystenkollegen eine
ganz explosive Sache ab! Schauen Sie nur was
Anfang 2000 mit dem Titel passiert ist: Nach
ähnlichen Nachrichten hat sich die ARIAD-Aktie
innerhalb von wenigen Monaten von USD 1 auf
USD 50 verfünfzigfacht. In den letzten 4 Wochen
ist die Aktie erneut kräftig angesprungen und
ist von 1,75 auf 4 Dollar gestiegen. Das ist aber
erst der Anfang. Das Neubewertungspotential
ist gewaltig. Wir empfehlen den Wert zum Kauf
und sind sicher, dass Sie damit die Chance
haben, auf Sicht von 12 Monaten zwischen 100
und 300% steuerfreien Gewinn zu erzielen! Die
WKN von ARIAD PHARMA lautet 895301.

quelle: http://www.hot-stocks-investor.de/
gruss
tb 2

[BrokerPK]

www.hotstock.de!!!
schreiben genau meine optimistische Meinung!!

da kommt früher od.später was sensationelles heraus!!

Trading-greetings

[thebull 2]

Tuesday March 12, 7:31 am Eastern Time

Press Release

SOURCE: ARIAD Pharmaceuticals, Inc.

ARIAD Appoints Chief Legal Officer

CAMBRIDGE, Mass.--(BW HealthWire)--March 12, 2002--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - news) today announced that Laurie A. Allen, Esq.,
formerly a partner of the law firm of Brobeck, Phleger & Harrison, LLP, was appointed chief legal officer, senior vice president and corporate secretary. In addition
to managing the Company`s corporate legal activities, she will play a key role in licensing and enforcing ARIAD`s broad patent portfolio, with special emphasis on its
pioneering NF-(kappa)B technology.

Ms. Allen served for the past two years as senior vice president, business development and legal affairs at Alexandria Real Estate Equities, Inc., a real estate
investment trust focused on the laboratory market, and practiced law for eight years at Brobeck, Phleger & Harrison, LLP, one of the nation`s leading technology
law firms. Ms. Allen`s law practice focused on business, securities, and intellectual property matters and managing litigation for life science companies. During 1999,
Ms. Allen was senior vice president and general counsel at ARIAD. She earned an L.L.M. in taxation from New York University School of Law and a J.D. degree
from Emory Law School.

``Ms. Allen`s appointment to our senior management team is further evidence of our assessment of the value of our NF-(kappa)B and other intellectual property
assets,`` said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company`s development
pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake by tumors to treat cancer; a bone-targeted drug candidate to treat the
complications of cancer that has spread to bone; a regulated protein therapy product candidate to treat anemia in which the production of erythropoietin is controlled
in vivo using an orally administered drug; a T cell immunotherapy product candidate in which a non-immunosuppressive drug may be used to treat graft-vs-host
disease following donor bone marrow transplantation - a therapy for cancer and other immune and blood diseases; and dual-action drug candidates that block bone
resorption and stimulate bone formation to treat osteoporosis. ARIAD also has an exclusive license to pioneering technology related to the discovery, development,
and use of drugs that modulate the NF-(kappa)B pathway, which has been implicated in many major diseases.

Additional information about ARIAD can be found on the web at www.ariad.com, including a new Chairman`s View on the Company`s product development
partnering strategy, which is not made a part of this press release.

Some of the matters discussed herein are forward-looking statements. Such statements are identified by the use of words such as ``anticipate,`` ``estimate,``
``expect,`` ``project,`` ``intend,`` ``plan,`` ``believe,`` and other words and terms of similar meaning in connection with any discussion of future operating or financial
performance. Such statements are based on management`s current expectations and are subject to certain factors, risks and uncertainties that may cause actual
results, events and performance to differ materially from those referred to or implied in such statements. These risks include, but are not limited to, risks and
uncertainties regarding the Company`s preclinical studies, the Company`s ability to conduct clinical trials of its product candidates and the results of such trials, as well
as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital
needs, dependence on the Company`s collaborators and other factors. These risks are identified in ARIAD`s Annual Report on Form 10-K for the fiscal year ended
December 31, 2000, filed with the Securities and Exchange Commission. The information contained in this document is believed to be current as of the date of
original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual
results or to changes in the Company`s expectations, except as required by law.

Contact:

ARIAD Pharmaceuticals, Inc.
Tom Pearson, 610/407-9260
Kathy Lawton, 617/494-0400

gruss
tb 2

[pauer1]

Das stimmt!

Nicht umsonst wird ARIAD überall empfohlen, aber langfristig.

[pauer1]

Gibt es was neues bei ARIAD?

++++++ 8%

[tobischlobi]

ich weiss nichts.. steigen aber seit einiger zeit und das bei hohen umsätzen -> gutes Zeichen!

[tobischlobi]

sehr sehr gute news heute von ariad:
aber hier ist mal wieder niemand an einem highflyer interessiert;
ach doch: da kauft ja jemand in D; jetzt +7%
-
ARIAD Lead Cancer Drug Candidate Shrinks Tumors Through Tumor Starvation; Late-Breaking News Presented at the American Association for Cancer Research Scientific Meeting
CAMBRIDGE, Mass., Apr 9, 2002 (BW HealthWire) -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today reported, for the first time, that studies on its orally
active drug candidate for cancer, AP23573, demonstrate potent tumor shrinkage
through a novel mode of action -- dramatic metabolic arrest and inhibition of
nutrient uptake in tumors leading to cancer-cell starvation. Animals with
implanted tumors treated with AP23573 at low doses for only five days showed
significant, sustained reduction in tumor volume even after termination of
treatment: 46% reduction in AP23573-treated animals vs. 150% increase in
untreated animals. Repeat treatment courses resulted in continued reduction in
tumor volume.

The effectiveness of AP23573 is particularly pronounced in cancer cells with a mutated tumor suppressor gene called PTEN, making it possible to identify cancer patients who would especially benefit from this drug candidate. Cancers with
PTEN mutation include prostate, uterine, pancreatic, and ovarian cancer, as well
as melanoma, leukemia, and glioma. AP23573 is in pre-IND development, undergoing studies required for regulatory filings to initiate clinical trials.

"The findings reported today at the American Association of Cancer Research scientific meeting represent a major advance in the development of a safe, non-cytotoxic cancer therapy, which is on track for starting clinical trials,"
said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.
"Eradicating tumors through metabolic starvation makes AP23573 an especially
promising drug candidate for the treatment of many of the most common and
difficult-to-treat cancers."

The abstract (LB-95) of the presentation by Clackson et al, "Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor
that induces tumor starvation," is available online at the AACR meeting website (www.aacr.org/2002AM/First/2002AM.html).

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company`s development pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake
by tumors to treat cancer; a bone-targeted drug candidate to treat the
complications of cancer that has spread to bone; a regulated protein therapy
product candidate to treat anemia in which the production of erythropoietin is
controlled in vivo using an orally administered drug; a T cell immunotherapy
product candidate in which a non-immunosuppressive drug may be used to treat
graft-vs-host disease following donor bone marrow transplantation -- a therapy
for cancer and other immune and blood diseases; and dual-action drug candidates
that block bone resorption and stimulate bone formation to treat osteoporosis.
ARIAD also has an exclusive license to pioneering technology related to the
discovery, development, and use of drugs that modulate the NF-(kappa)B pathway,
which has been implicated in many major diseases.

Additional information about ARIAD can be found on the web at www.ariad.com, including a new Chairman`s View on the Company`s product development partnering
strategy, which is not made a part of this press release.

Some of the matters discussed herein are forward-looking statements. Such statements are identified by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance. Such statements are based on management`s current
expectations and are subject to certain factors, risks and uncertainties that
may cause actual results, events and performance to differ materially from those
referred to or implied in such statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company`s preclinical studies,
the Company`s ability to conduct clinical trials of its product candidates and
the results of such trials, as well as risks and uncertainties relating to
economic conditions, markets, products, competition, intellectual property,
services and prices, key employees, future capital needs, dependence on the
Company`s collaborators and other factors. These risks are identified in ARIAD`s
Annual Report on Form 10-K for the fiscal year ended December 31, 2001, filed
with the Securities and Exchange Commission. The information contained in this
document is believed to be current as of the date of original issue. The Company
does not intend to update any of the forward-looking statements after the date
of this document to conform these statements to actual results or to changes in
the Company`s expectations, except as required by law.

CONTACT: ARIAD Pharmaceuticals, Inc.
Tom Pearson, 610/407-9260
Kathy Lawton, 617/494-0400

[tobischlobi]

so jetzt hat jemand doch noch seine chance wahrgenommen und ariad in D billig gekauft, denn auch die +10% sind noch wenig zu dem was noch kommen wird, aber wahrscheinlich glaubt mirs wieder keiner. ich habe auch schon bei kursen um 4,5€ zum einkaufen empfohlen, jetzt stehen sie aktuell bei 6,2 und die meldung von heute hat die usa noch nicht bewertet.

[gholzbauer]

Wär ja schön, wenn es nicht nur wieder ein Strohfeuer wird.

[tobischlobi]

wohl eher nicht, der kurzfristige aufwärtstrend ist doch einwandfrei. warum die gestern so abgaben? keine ahnung, aber die heutige meldung ist ein erfolg. klinische test sind nun an der reihe -> das sind große schritte !

[tobischlobi]

übrigens in usa erster kurs +15% Umsätze hoch, also M.E. nach gehts steil nach oben!

[tobischlobi]

haben schon soviel umgesetzt wie die wochen zuvor an einem tag. kurs geht ab durch die mitte!

in D kommt man in Frankf. (+11%) noch günstig ran in USA schon +19%

[tobischlobi]

UMSÄTZE WIE SAU!!!!!!!!!

[tobischlobi]

ich kauf jetzt die billigen stücke in fra; in usa gehts ab und hier mal wieder alle zu doof dafür (sorry, war nicht böse gemeint)

[tobischlobi]

hab zu 6,34 nachgekauft. einstand jetzt bei 5,3. mal sehen wo es heute hingeht in usa. wir hinken ja meist hinterher hier. wenn usa so bei +15 - +20% endet bei ungeheuer hohen umsaätzen, dann ist das wunderbar. der kurs in D läuft dann automatisch mit.

[tobischlobi]

möchte jemand mal den kurs wissen? in usa +25%! und das bei RIESIGEN umsätzen

[BrokerPK]

kann mir jemand mal diese News übersetzen??
haben die Krebs-Antikörper eingeschlagen wohl hm!?!?

wahnsinn!!

morgen gehts bei uns auch nochmal ab!!
wir haben ja noch 10% aufzuholen!!

Ariad Rakete ist gestartet!!
Altersvorsorgepaket)!!

[tobischlobi]

es geht dabei um folgendes:

mittel zur bekämpfung von tumoren, die schwer behandelbar sind.
ergebnis an tieren bei fünftägiger verabreichung des mittels: veringerung um etwa 45%; ohne behandlung: wachstum des tumors um ca.150%

[somart]

Nachbörslich in den Usa -8%

[tobischlobi]

wo ist dieser kurs her? link?

[tobischlobi]

hätte mich schon interessiert. glaube aber sowieso nicht, dass die heute 8% fallen

[Andreolly]

Würde mich mal über eine chartechnische Analyse interessieren. Kann es unter Umständen sogar bis 15 USD gehen?

[tobischlobi]

wenn wir über die 6,14 Dollar wégkommen würden, dann kanns auch bis 15 hochgehen. näheres später

[tobischlobi]

wir sind seit einem jahr grob gesehen seitwärts gelaufen, dabei sind die 6,14 dollar die obere grenze gewesen.
die umsätze haben in letzter zeit zugenommen, hat wohl auch was mit dem eingestiegenen fond zu tun. rsi ist ok. haben zur zeit aber eine leichte tendenz zum überkauft sein. rückschlagspotential besteht. mittelfristig sieht es aber gut aus charttechnisch. die 14$ sind auch das kursziel eines analysten:

10.12.2001
Ariad Pharmaceuticals "strong buy"
Ladenburg Thalmann

Rating-Update:

Die Analysten vom Investmenthaus Ladenburg Thalmann stufen die Aktie von Ariad Pharmaceuticals (WKN 895301) unverändert mit "strong buy" ein. Das Kursziel sehe man bei 14 US-Dollar.

SEHE GERADE EINE NEUE KAUFEMPFEHLUNG:

16.04.2002
Ariad Pharmac. spekulativ kaufen
juchu.de

Die Wertpapierexperten von "juchu.de" raten die Aktien von Ariad Pharmaceuticals (WKN 895301) spekulativ zu kaufen.

Ariad Pharmaceuticals habe vergangene Woche über Studien zu ihrem neuen Krebs-Medikament "AP23573" berichtet. Demnach seien die Tierversuche sehr erfolgreich verlaufen. Die Tumorzellen hätten sich nach Gabe des Medikaments deutlich zurückgebildet und seien sogar schließlich ganz abgestorben. Bei Tieren ohne Behandlung habe sich der Tumor nach fünf Tagen um ca. 150% vergrößert, bei den Versuchstieren seien die Tumore um 46% zurückgegangen.

Daher stufen die Analysten von "juchu.de" die Aktien von Ariad Pharmaceuticals mit "spekulativ kaufen" ein.

(QUELLE: www.aktiencheck.de)

[tobischlobi]

hier nochmal mein posting zum fondmanager:

#10 von tobischlobi 14.04.02 23:21:18 Beitrag Nr.: 6.122.542 6122542
Dieses Posting: versenden | melden | drucken


es gibt was neues. fondmanager hat ARIAD als top stock pick empfohlen und kauft ARIAD auch selbst in seinen Fonds ein:
dass das gut für den kurs ist, ist klar, oder?

hier der artikel vom 11.04:

Combing for value
Isabelle likes Ariad, iDine, Commonwealth Industries

By Leticia Williams, CBS.MarketWatch.com
Last Update: 12:06 AM ET April 11, 2002

WASHINGTON (CBS.MW) -- Fund manager Warren Isabelle casts his net in a number of industries when picking stocks for his value-based ICM Small-Cap fund.

"Our valuation methodology is based on finding companies with market prices significantly less than what their economics would warrant for value," Isabelle said. "We`ll go to any industry to find these values."

The fund (IZZYX: news, chart, profile) is up 13 percent this year, compared to a 1.08 percent drop by the S&P 500 Index. Its three-year annualized return is 26.98 percent, compared to a loss of 5.7 percent by the S&P.

His first pick is aluminum fabricating firm Commonwealth Industries (CMIN: news, chart, profile). The company is "poised for a recovery" after lowering inventory, cutting costs and slashing debt during the economic downturn, the manager said. "Based on operating potential, the leverage these guys will show on the upside could be significant," he said. Shares rose 20 cents to $8 on Wednesday.

Isabelle`s second pick is biotech company Ariad Pharmaceuticals (ARIA: news, chart, profile). The Cambridge, Mass.-based firm said Tuesday that studies of its orally active drug candidate for cancer have demonstrated "potent tumor shrinkage" through metabolic arrest and inhibition of nutrient uptake in tumors. See story. Shares were down 30 cents to $5.36.

Lastly, the manager likes dining credit card company iDine Rewards Network, formerly known as Transmedia Network. The Miami, Fla.-based company (IRN: news, chart, profile) offers members dining savings and reward programs at restaurants throughout the U.S. "This company is on the cusp of producing marked growth and revenues," Isabelle said. Shares traded at $8.99, up 9 cents.

Leticia Williams is a reporter for CBS.MarketWatch.com in Washington.

[gholzbauer]

Ariad Pharmac. interessant
Quelle: DER AKTIONAER
Datum: 16.04.02

Die Aktie von Ariad Pharmaceuticals ist den Analysten von "Der Aktionär-online" zufolge ein interessantes Investment. Erst einige Tage sei es her, dass der Kurs des US-amerikanischen Unternehmens Ariad Pharmaceuticals einen Sprung von 18% gemacht habe, nachdem das Unternehmen erste aussichtsreiche präklinische Studiendaten seines experimentellen Krebswirkstoffes, mit der Bezeichnung AP23573, veröffentlicht habe. Ariads Pipeline enthalte jedoch neben AP23573 noch weitere sehr interessante Kandidaten. Fast sämtliche Produktkandidaten seien unter Nutzung der von Ariad entwickelten »Cell-Signaling Regulation Technology«, die übrigens weltweit von mehr als 500 akademischen Forschungsinstituten zur Entwicklung der verschiedensten Medikamente genutzt werde, erforscht und entwickelt worden. Diese Technologie komme im übrigen auch zur Entwicklung neuer Stammzellen-Therapien für genetische Erkrankungen des Blutes sowie zur Erforschung und Weiterentwicklung von Krebsvakzinen zum Einsatz. Für eine Pionier-Technologie zur Erforschung, Entwicklung und Nutzung von Substanzen, welche in den NF-(kappa)B Stoffwechselweg, der bei einer Vielzahl von Krankheiten eine wichtige Rolle spiele, eingreifen würden, besitze Ariad die Exklusivlizenz. Durch die aggressive Weiterentwicklung der fünf wichtigsten Produktkandidaten sei es im Jahr 2001 gegenüber dem Vorjahr zu einer Ausweitung des Nettoverlustes von 3,8 Mio. US-Dollar auf 19,8 Mio. US-Dollar gekommen. Die Ausgaben für Forschung und Entwicklung seien dabei um 33% von 12,5 Mio. US-Dollar auf 16,6 Mio. US-Dollar gestiegen. Die Cash-Reserven sowie das Betriebskapital der Gesellschaft hätten sich aber von 39,8 Mio. US-Dollar und 36,9 Mio. US-Dollar im Vorjahr auf 47,2 Mio. US-Dollar und 42,8 Mio. US-Dollar zum 31. Dezember 2001 erhöht. Sollte Ariad seine aggressive Produktentwicklungsstrategie weiterhin so konsequent verfolgen, dürften sich der Kostenaufwand für das Unternehmen vielleicht schon früher als geplant amortisieren. Nach Meinung der Analysten von "Der Aktionär-online" ist die Ariad-Aktie ein interessantes Investment.

© aktiencheck.de AG

[tobischlobi]

witzig, dass die das jetzt auchgemerkt haben :-)

[gholzbauer]

Nachden "Der Aktionär" schon so oft in den Dreck gegriffen hat, bin ich gar nicht erfreut über diese Empfehlung.

Augen zu und durch oder so ...

Morgen kommt womöglich noch die Benachrichtigung, daß es mit den Phase-II-Tests zum GvHD-Projekt doch nicht so geklappt hat. Man lasse sich nur nicht durch ein "positive Result" in der Überschrift täuschen.

[tobischlobi]

nun, auch die förtschianer können nicht immer daneben liegen. und, da die in usa stark gehandelt wird, können hier ein paar lemminge nichts kaputt machen..

[gholzbauer]

http://moneycentral.msn.com/content/CNBCTV/Articles/StockPic…

Stock Picks
June 20, 2002 01:30 PM ET
Choose small caps for value, says portfolio manager

Exogenous events such as terrorism and the possibility of nuclear war—coupled with worries over whether the economy can sustain any significant growth—have the market confused, says Warren Isabelle, portfolio manager of ICM/Isabelle Small Cap Value Fund.

Thursday’s Power Portfolio guest on CNBC’s Power Lunch believes that in such a market environment, small caps are the place to be. He says they’ve done well recently, but only because the big-stock syndrome of the late `90s has collapsed. Isabelle believes this move was premature, and that small caps will rise again, because these stocks traditionally rise on economic pickups since they`re the most responsive to favorable changes.

During his on-air interview, Isabelle discussed five stocks—two chemicals, two biotechs and one aluminum fabricator—that he says add up to “all value.” We also included his comments. Use the CNBC.com on MSN tools for more information on each pick.

...

ARIAD Pharmaceuticals, Inc.

•
Local biotech firm focused on cell signaling, primarily aimed at cancer but also has new possibility for osteoporosis
•
Has been severely depressed along with sector, with skeptics citing no near-term drugs in pipeline
•
However, science is excellent, and company could have as many as five drugs in phase two clinical trials by late 2003
•
Key is ability to commercialize intellectual property within reasonable time frame
•
Market value tiny vs. huge portfolio potential
•
Hidden value may be in intellectual property licensing for Nf-KB, considered one of the master regulators of key genes
•
Price target is greater than $20



...

[gholzbauer]

Jetzt geht`s los.
Damit hätte Ariad auf einen Schlag zwei zugelassene Medikamente, sozusagen.



------


Tuesday June 25, 10:58 pm Eastern Time

Associated Press
Ariad Sues Eli Lilly on Patent

Ariad Pharmaceuticals Sues Eli Lilly Claiming Patent Infringement

CAMBRIDGE, Mass. (AP) -- Ariad Pharmaceuticals, Inc. filed a lawsuit in federal court in Boston on Tuesday claiming Eli Lilly and Co. (NYSE:LLY - News) infringed on its patents through the sale of septic shock and osteoporosis drugs.


Ariad claimed two drugs produced by Lilly, Evista and Xigris, infringe on technology, which treats human disease by regulating certain cell-signaling activity, developed by collaborators of Ariad.

Ariad claims an exclusive license to the technology, which was developed by the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research and Harvard University.

Ariad, which will be managing the litigation on behalf of the other plaintiffs, will be represented by the New York law firm of Clifford, Chance, Rogers & Wells.

"Lilly has ignored our prior efforts to initiate discussions concerning a license to our family of NF-(kappa)B patents, even as Lilly scientists were publishing scientific proof that the use of Evista and Xigris are covered NF-(kappa)B treatment methods," said Harvey J. Berger, chairman and chief executive officer of Ariad.

Ariad is seeking unspecified monetary damages, but envisioned reaching a settlement based on royalty payments on the sale of the two Lilly drugs, Berger said.

Industry analysts have projected that both drugs eventually may exceed $1 billion in annual sales, Ariad said in a statement.

Messages left with Eli Lilly`s Indianapolis headquarters were not immediately returned.


---------



Tuesday June 25, 7:11 pm Eastern Time

Press Release

SOURCE: ARIAD Pharmaceuticals, Inc.

ARIAD Announces Issuance of Pioneering Patent on Treating Human Disease by Regulating NF-kappa-B Cell Signaling

Implications for Treatment of Inflammation, Cancer and Osteoporosis

CAMBRIDGE, Mass.--(BW HealthWire)--June 25, 2002--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced the issuance of a pioneering U.S. patent covering methods of treating human disease by regulating NF-(kappa)B cell-signaling activity. The use of many currently marketed drugs and products in development are examples of such NF-(kappa)B treatment methods. These drugs collectively have markets of several billion dollars annually. The newly issued U.S. patent is one of a family of patents, three in the U.S. and one in Europe, awarded to a team of distinguished scientists from the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, and Harvard University in recognition of their pioneering research on NF-(kappa)B as a master regulator of cell signaling. ARIAD has an exclusive license to these patents. The latest patent includes 203 claims and provides coverage relating to NF-(kappa)B treatment methods through the year 2019.

The NF-(kappa)B protein, encoded by two of the estimated 35,000 genes in the human genome, is among the body`s most important known regulators of cellular function. The activity of NF-(kappa)B has been implicated in several difficult-to-treat disease conditions, including inflammation (e.g., atherosclerosis, arthritis, inflammatory bowel disease, rheumatoid arthritis, and septic shock), malignant transformation and tumor growth (e.g., certain blood cancers and solid tumors), and bone breakdown and rebuilding (e.g., osteoporosis). NF-(kappa)B can be generally thought of as a "biological switch" that can be turned off in cells to treat these diseases.

"Landmark science has been the guiding principle of ARIAD since its founding. When we obtained an exclusive license to the NF-(kappa)B technology in 1991, few in the pharmaceutical industry recognized the profound clinical and commercial implications of this pioneering work. Ten years and thousands of scientific papers later, the impact of this discovery on treating human disease has become widely appreciated," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Dr. Berger added, "We are committed to creating value for the team of inventors and their institutions and are actively pursuing a licensing program for our portfolio of patents on NF-(kappa)B. Our goals are to acknowledge the important contributions made by our academic colleagues and to help underwrite the cost of developing and commercializing our portfolio of breakthrough medicines that regulate cell signaling. Many of today`s top-tier biotech companies, such as Biogen, have successfully used patent-licensing revenues to help build their leadership positions in our industry."

NF-(kappa)B may be activated by any one of several different signals originating outside the cell, including various inflammatory cytokines (e.g., TNF- (alpha), IL-1, and IL-6), bacterial and viral infections (e.g., lipopolysaccharide), and cancer-causing proteins (e.g., oncogenic proteins). NF-(kappa)B generally resides in the cell bound to its naturally occurring inhibitor, which prevents NF-(kappa)B from entering the nucleus. When cells are activated, the inhibitor protein usually becomes modified and subsequently is broken down by proteasomes -- enzyme complexes in the cell responsible for breaking down such proteins. This frees NF-(kappa)B to move into the nucleus where it regulates the expression of key genes involved in immune and inflammatory responses, as well as cellular growth, control and death. Specific genes encoding certain cytokines, cytokine receptors, cell adhesion molecules, chemo-attractant proteins, oncoproteins, and growth factors may be regulated by NF-(kappa)B.

Built upon the initial discoveries by the distinguished team of inventors, this fundamental understanding of the role of NF-(kappa)B in human disease has facilitated the discovery of drugs that inhibit or modulate NF-(kappa)B cell signaling activity for use in both chronic and acute diseases.

The team of NF-(kappa)B inventors was led by Dr. David Baltimore, former Director of the Whitehead Institute and Institute Professor at M.I.T., now President and Professor of Biology at the California Institute of Technology; Dr. Phillip Sharp, Institute Professor and Director of the McGovern Institute for Brain Research at M.I.T.; and Dr. Thomas Maniatis, Thomas H. Lee Professor of Molecular and Cell Biology at Harvard. Drs. Baltimore and Sharp are recipients of the Nobel Prize in Medicine or Physiology, and Dr. Baltimore is a founding member of ARIAD`s board of scientific and medical advisors. Their laboratories have worked for over twenty years on NF-(kappa)B and related areas of cell signaling and gene regulation.

Other NF-(kappa)B inventors and their current affiliations include: Dr. Patrick Baeuerle, Professor of Immunology at the University of Munich; Dr. Albert Baldwin, Professor of Biology, Genetics and Molecular Biology at the University of North Carolina; Dr. Roger Clerc, Senior Scientist at F. Hoffmann-LaRoche Ltd.; Dr. Lynn Corcoran, Senior Research Fellow at The Walter and Eliza Hall Institute of Medical Research; Dr. Chen-Ming Fan, Adjunct Professor of Biology and Embryology at the Carnegie Institution of Washington; Dr. Jonathan LeBowitz, Associate Professor of Biochemistry at Purdue University; Dr. Michael Lenardo, Section Head, Laboratory of Immunology at the National Institutes of Health; Dr. Ranjan Sen, Professor of Biology at Brandeis University; Dr. Harinder Singh, Professor of Molecular Genetics and Cell Biology at the University of Chicago; and Dr. Louis Staudt, Senior Investigator, Center for Cancer Research at the National Institutes of Health.

A copy of the newly issued U.S. patent, "Nuclear Factors Associated with Transcriptional Regulation" (No. 6,410,516), is available at the website of the U.S. Patent and Trademark Office (http://164.195.100.11/netahtml/srchnum.htm) or at a link from ARIAD`s website (http://www.ariad.com/patents). A list of selected NF-(kappa)B scientific papers and references is also available at ARIAD`s website (http://www.ariad.com/related_resources).

[puhvogel]

Das trifft ELi Lilly ins Mark, wenn die damit durchkommen.

[gholzbauer]

Selbst, wenn ARIA nur niedrige einstellig-prozentige (1-3%?) Royalties auf alle Medikamente, die das Target betreffen, bekommen würde, wäre es ein Riesending.
Andererseits kann ich mir nicht ganz vorstellen, daß man ein Patent auf einen biochemischen Vorgang derart nutzen kann.
Wiederum andererseits: das MIT(!) und Harvard(!) sind mit ARIA.



Ob es dem Kurs kurzfristig nutzt, steht aufgrund der WorldCom-Panik auf einem anderen Blatt.

[gholzbauer]

Jetzt wird mir auch klarer, warum es mit der Phase II so lange dauert.
Die haben die ganze Zeit am Produktionsprozeß rumgebastelt.



Press Release
Source: ARIAD Pharmaceuticals, Inc.

ARIAD Announces New Clinical-Scale Production Methods for Its Graft-vs-Host Disease Product Candidate
Patients Undergoing Bone Marrow and Stem Cell Transplants For Cancer Targeted
Thursday September 5, 7:32 am ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 5, 2002--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced development of new clinical-scale methods for producing large numbers of therapeutic engineered donor T cells - an important milestone in the phase 2 development of the Company`s product candidate to treat graft-vs-host disease. The work was conducted by a collaborative team of scientists from the Fred Hutchinson Cancer Research Center, Seattle and ARIAD and is described, for the first time, in a paper published in the journal Blood.

ADVERTISEMENT

This advance achieves several important product development objectives. The production method can be conducted in specialized facilities within hospitals performing bone marrow and stem cell transplants, run at clinical scale and partially automated. In separate preclinical studies, highly purified donor T cells obtained with this process retain normal immune, anti-infective, and anti-cancer activity, cellular viability, and lack of toxicity - comparable to unmodified T cells. In addition, the engineered cells can be potently and rapidly eliminated by administration of ARIAD`s small-molecule drug, AP1903.

"This study from one of the leading transplant centers provides compelling support for the development of our T cell immunotherapy product candidate to treat graft-vs-host disease. The findings reflect the great care that has been taken in designing clinically relevant systems that yield highly functional immune cells for therapeutic use. The newly developed cell-processing methods will enable us to advance our phase 2 development program," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Graft-vs-host disease occurs when donor T cells, given after certain types of bone marrow or stem cell transplants to augment the patient`s immune system, attack the patient`s own tissues, which contributes to the morbidity and mortality of the transplant. Many patients who could benefit from such transplants, especially those with advanced-stage cancer, cannot receive this potentially curative therapy because of the risk of developing life-threatening graft-vs-host disease.

The paper by Berger, C., et al, entitled "CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy," was carried out in the laboratories of Stan Riddell, M.D. and Shelly Heimfeld, Ph.D. and appears in the online issue of Blood which is accessible at the journal`s website (http://www.bloodjournal.org/).










Press Release
Source: Rodman & Renshaw Inc.

Rodman & Renshaw Inc. Initiates Coverage of Ariad Pharmaceuticals, Inc. With a Market OutPerform
Thursday September 5, 3:45 pm ET

NEW YORK, Sept. 5 /PRNewswire/ -- Rodman & Renshaw`s Senior Biotechnology Analyst, Elemer Piros, Ph.D. has initiated coverage of Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA - News) with a Market Outperform and an 18-month price target of $11. Following initiation on Cepheid (Nasdaq: CPHD - News) in June, the Ariad recommendation signals Rodman & Renshaw`s continuing commitment to small- and mid-cap quality growth companies.

Dr. Piros, formerly a buy-side analyst at Spear, Leeds & Kellogg (now a wholly-owned subsidiary of Goldman Sachs) stated, "We are initiating coverage of Ariad with a Market Outperform/Speculative Risk rating. Over the next 6-15 months, Ariad will enter human clinical testing with four additional programs addressing large unmet medical needs. The transition from a research-oriented biotech company to a developer of drugs with a focus on cancer and blood diseases represents an important milestone in Ariad`s history. In our view, the transition should galvanize investor interest."

Among Ariad`s most promising developments may be the licensing of NF-(kappa)B treatment method patents. According to Dr. Piros, "The company has licensed the patents describing one of the most fundamental signaling molecules in medicine, NF-(kappa)B. Ariad has filed a lawsuit against Eli Lilly (NYSE: LLY - News) claiming infringement by two marketed drugs. While it is difficult to handicap the outcome of the litigation, we believe success would mean hundreds of millions of dollars in royalty payments to Ariad providing the funds to fully develop Ariad`s drug portfolio."

Dr. Piros believes Ariad`s shares are undervalued, "We have evaluated the market potential of Ariad`s programs, remaining R&D expense and probability of success. In our calculation, the sum of the net present value of the portfolio exceeds $300M (by YE03). Based on current market valuation of less than $100M, we believe that Ariad shares are undervalued."

Rodman & Renshaw`s recommendation on Ariad takes into account the realization that commercial potential of any drugs entails risks of receiving FDA approval and substantial costs in bringing new drugs to market against much larger, entrenched competitors. Consequently, we assign a Speculative Risk rating to the stock.

For further information about Ariad or a copy of the entire research report, please contact Christine Viola at 212-356-0505 or at [e-mail]

[gholzbauer]

Kursziel 8$ wäre aber vermutlich tief gegriffen, wenn Ariad mit dem Patent und den Klagen durchkommt.
$$$$$$




6:10AM Ariad Pharm surges on favorable court ruling (ARIA) 2.24: Ariad Pharm shares rose 70% in after hours trading after the co announced that a U.S. District Court has ruled in favor of Ariad and co-plaintiffs in a patent infringement suit filed against Eli Lilly (LLY) alleging infringement of their pioneering U.S. patent covering methods of treating human disease by regulating NF-(kappa) B cell-signaling activity. Rodman & Renshaw is out with a positive note commenting that after the ruling vs. LLY they expect one or more of the 50 companies with NF-kB-related products to sublicense ARIAD`s patent estate. The analyst is reiterating his price target of $8 for ARIA. Of note, Velcade, the newly approved multiple myeloma drug by MLNM is among the 50 products related to NF-kB action making the co a potential licensee of the ARIAD patents.

[mimimouse]

Der Bericht sieht doch positiv aus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2003--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the United States District Court for the District of Massachusetts (the Court) has ruled in favor of ARIAD Pharmaceuticals, Inc. and co-plaintiffs in a patent infringement suit filed on June 25, 2002 against Eli Lilly and Company (Lilly) alleging infringement of their pioneering U.S. patent covering methods of treating human disease by regulating NF-(kappa)B cell-signaling activity. The lawsuit alleges infringement by Lilly through sales of its osteoporosis drug, Evista(R), and septic shock drug, Xigris(R). The Court denied Lilly`s combined motion to dismiss and its motion for summary judgment challenging the validity of the NF-(kappa)B method of treatment patent claims. The co-plaintiffs are Massachusetts Institute of Technology, The Whitehead Institute for Biomedical Research and The President and Fellows of Harvard College.

"We are very pleased with the Court`s ruling," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Our objective now is to proceed expeditiously to trial and to seek a damage award based on a reasonable royalty on Lilly`s sales of Evista and Xigris, as we continue to pursue additional licenses of our NF-(kappa)B patent portfolio."

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company is developing a comprehensive approach to the treatment of cancer and is primarily focused on a series of product candidates for targeted oncology indications. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs that regulate NF-(kappa)B cell-signaling activity, which has been implicated in many major diseases.

Wie ist eure Meinung?

[4myRetire]

News

Neuer Vorstand bei Ariad Pharmaceuticals

Die Ariad Pharmaceuticals Inc. meldet die Ernennung eines neuen Vorstandes. Das frühere Vorstandsmitglied der Novartis AG, Paul Sekhri, wird demnach zukünftig das Amt des Chief Business Officer und des President bei Ariad übernehmen.

Bevor Sekhri zum Biotechnologieunternehmen Ariad kam, war er bei der Sprout-Gruppe, der Venture Capital-Sparte von Credit Suisse First Boston, tätig. Zudem hatte er bereits Posten bei mehreren Unternehmen im Gesundheitswesen und bei Consulting-Firmen inne.

Die Aktie von Ariad steigt an der NASDAQ auf 6,87 Dollar.

Potential bis 11 Dollar.

[borazon]

Um es festzuhalten - s. weiter unten stehenden Text.


Jedoch nach einem Anstieg vom Tief bei 1,xx$ auf jetzt 9$ werde ich erst mal wieder etwas Kasse machen.
>400 mln MktCap sind vorerst OK, aber nicht billig.

Wundert mich übrigens, daß der Prozeß vs. LLY und die Lizenzgeschichten völlig vernachlässigt werden.







Dow Jones Business News
Ariad Shares Climb in Wake of Positive Analyst Comments
Wednesday February 11, 1:45 pm ET
By Mohammed Hadi

NEW YORK -- Shares of Ariad Pharmaceuticals Inc. (NasdaqNM:ARIA - News) rose Wednesday after an analyst at Lehman Brothers Inc. described the drug developer as the next promising name in oncology and touted the potential of two products currently in its pipeline.

In a note to clients, Lehman analyst Jim Birchenough focused on Ariad`s lead leukemia treatment, AP23464, which is currently in preclinical development, and cancer treatment, AP23573, which is in Phase I clinical trials.

Mr. Birchenough initiated coverage of Ariad with an "overweight" rating and a $13 price target. The analyst doesn`t own Ariad shares. Lehman Brothers has received compensation from the company for investment-banking services. Lehman also makes a market in Ariad securities.

He is the second analyst to initiate coverage in two weeks, noted Ariad`s Chairman and Chief Executive Harvey J. Berger in an interview with Dow Jones Newswires. He cited the increased coverage as a possible reason behind the rising stock price.

In December, Ariad said AP23464 was highly effective in blocking the growth of certain leukemia cells that are resistant to Novartis AG`s (NYSE:NVS - News) Gleevec.

Gleevec generated about $1.13 billion in sales in 2003, about $299 million of which were in the U.S., Novartis recently said.

Although AP23464 is still in early development stages, Mr. Birchenough thinks the drug`s ability to work on patients who are resistant to Novartis` Gleevec could "provide a basis for accelerated approval."

Ariad has an eye towards applying for accelerated approval for AP23464, but Dr. Berger noted that such an application is largely dependent upon Food and Drug Administration (News - Websites) concurrence.

JMP Securities analyst Howard Liang pointed out that Gleevec was approved by the FDA within 32 months of beginning Phase I trials.

Mr. Liang, who doesn`t own any of the company`s stock, noted that neither AP23464 nor AP23573 will reach the market until 2007, but said his $12 price target and "overweight" rating for the stock are backed by both drugs` potential to reach a pivotal stage of development that could ultimately support a new-drug application.

Dr. Berger hopes Ariad`s development plans will yield definitive clinical data on both products sometime in 2005 and the company hopes to get to market by 2006 or 2007.

At about 1:30 p.m. EST on the Nasdaq Stock Market (News - Websites) , Ariad shares were up $1.13, or 15%, at $8.64 on volume of 1.9 million, compared with average daily volume of 670,100.

JMP Securities makes a market in Ariad`s shares, and may seek investment- banking business from the company, Mr. Liang said.

Ariad`s cancer treatment, AP23573, has "demonstrated prominent antiproliferative activity against several types of cancers," Mr. Birchenough said in his note.

While that drug is in early stages of development, it is validated by a similar cancer treatment being developed by Wyeth (WYE), which is in Phase III trials, noted Mr. Liang of JMP Securities.

Phase II trials for AP23573 are expected to begin in the second quarter, and although the company has yet to identify what specific areas of treatment will be studied at that stage, Mr. Birchenough thinks the drug may be developed for less competitive areas such as hepatocellular carcinoma, a form of liver cancer, and thyroid cancer.

Mr. Liang thinks AP23573 also has a chance for accelerated approval, but noted that the company hasn`t yet outlined a strategy for its development.

Ariad`s CEO Dr. Berger said the company has decided to develop the drug for multiple solid tumors and blood cancers but hasn`t identified which specific ones Ariad will target.

Ariad plans to provide an update on its progress in upcoming oncology meetings, he said, and has applied to present initial data from Phase I trials at the annual meeting of the American Society of Clinical Oncology in June.

More general updates on the company`s oncology program will be made at the Protein Kinases and Cancer meeting at the end of February and the American Association for Cancer Research annual meeting at the end of March, Dr. Berger said.

"We would recommend accumulating (Ariad) shares in advance of these meetings," Mr. Birchenough wrote.

Mr. Birchenough also noted that the company has other development options, including a version of AP23573 that could be used in drug-eluting stents.

Dr. Berger said the company is actively negotiating with potential partners to develop those stents, and hopes to make an announcement about that "reasonably soon."

In addition, a third drug is in preclinical development as a treatment for bone cancer, Dr. Berger said.

-By Mohammed Hadi, Dow Jones Newswires; 201-938-5400

[tobischlobi]

weiss jemand mehr über die präsentation am 10. märz, die live übertragen werden soll??

interessiert sich eigentlich niemand für diese aktie??

[felina]

Also ich bin von der Aktie überzeugt und hoffe, dass sie aufgrund der klinischen Studien in den nächsten 1-2 jahren auf 20 Dollar steigt.Immerhin kommt sie von fast 40 vor 3 jahren.Und jetzt kommt langsam Butter bei die Fische.
übrigens immer interessant:www.ariad.com

[tobischlobi]

Hat in usa über 11 Dollar geschlossen.
bin auf den 10 märz gespannt.

[Chlorophyll]

Hallo
Bin auch seit 2002 dabei. Habe damals als paur1 in diesem Board geschrieben hatte, dass bei 6$ der Boden gefunden ist
gekauft. Bin auch sonst überzeugt von diesem Wert und hoffe, dass er über 10$ steigt bis 20$ wäre zu schön.

[Zampano]

Was hätte denn am 10.03.04 Live übertragen werden sollen???
Bin schon seit 2001 investiert und würde gerne bei 15-20$ Kasse machen.
Ist dieser Kurs denn überhaupt noch realistisch oder sind die Prozeßkosten für Ariad dafür zu groß?

[zuzuiop]

weiß jemand wieso ariad heute so steigt
hab selber keine news gefunden ?
mfg.zuzu

[bernie55]

12,65 €

auch heute wieder.....up to the sky......
mfg bernie

[bernie55]

oooooohhh sorry.....12,65 $


mfg bernie

[tobischlobi]

Was ist denn bei Ariad los.
steigt und steigt und steigt
ohne news???

habe soeben mein kursziel erreicht und per sl abgesichert. alles weitere ist eine zugabe.

[borazon]

Weiß nicht, ob es stimmt, aber ich stells mal rein ...
(außerdem sollen angeblich heute Lehman Bros. Ariad auf "outperform" bestätigt (reiterated) haben)



http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…


ARIA UPGRADE
by: startraderdow
Long-Term Sentiment: Strong Buy
04/26/04 12:44 pm
Msg: 49627 of 49664


There was an upgrade by JMP today details


ARIA target raised to $16 at JMP (12.39 +0.86)

JMP Securities says it expects important news flow for Ariad Pharma (ARIA) surrounding the upcoming ASCO meeting. In conjunction with the first presentation of clinical data on lead compound AP23572 (`573, mTOR inhibitor) at the American Society for Clinical Oncology (ASCO) on June 7, the firm expects the co to unveil an ambitious, comprehensive clinical program for `573 before the conference during the week of May 24. There may be several potentially accelerated regulatory paths for `573, and data to be presented at ASCO on other mTOR inhibitors could shed light on some of the potential indications. With the advancement of `573 into Phase II development, the firm believes Ariad is evolving into a premier mid-stage oncology company. Raises target to $16 from $12.

[haggibaer]

@ Alle

Habe Ariad schon länger nicht mehr beobachtet.

Warum gings nach dem April HIGH wieder so runter ?
Vielen Dank für Eure Info`s

Haggi

[borazon]

Neben Ariad hat es auch einige andere auf Krebs fokussierte Biotechs erwischt.
Die vorangegangenen Anstiege waren einfach zu stark (z.B. hatten sich Ariad zwischen März 2003 und dem letzten Hoch bei 13,74$ ca. verzehnfacht und eine Mkt Cap über 600 Mio $ - das konnte schwerlich gutgehen) und insbesondere die Erwartungen bzgl. Neuigkeiten zur ASCO und zur Needham Biotech Conference waren zu hoch.

Mein Plan weiterhin:
Unter 4(3?)$ kauf ich wieder, über 8-10$ wird wieder gegeben.

[bernie55]

ZUR INFO FÜR ARIAD-AKTIONÄRE

Press Release Source: ARIAD Pharmaceuticals, Inc.


ARIAD Initiates Phase 2 Clinical Trial of AP23573 in Patients with Relapsed and/or Refractory Sarcomas
Thursday September 30, 7:05 am ET
First global multicenter Phase 2 clinical trial of AP23573 in solid tumors


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 30, 2004-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced initiation of enrollment of patients with bone and soft tissue sarcomas in the first multicenter Phase 2 clinical trial of its novel mTOR inhibitor, AP23573, as a single agent in solid tumors.
ADVERTISEMENT


This non-randomized study will evaluate the clinical benefit of AP23573 in four well-defined groups of sarcoma patients, characterized by tumor type. Up to approximately 175 patients will be enrolled in the trial at approximately 15 centers in the United States and Europe. AP23573 will be administered using a daily dosing regimen of drug.

"In our nearly completed Phase 1 clinical trials reported today at the EORTC international cancer symposium, all evaluable patients with relapsed and/or refractory sarcoma had evidence of anti-tumor activity - a promising result that supports our decision to further evaluate AP23573 in this patient population in Phase 2," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Despite advancements in anti-cancer therapy, currently available treatment options for such patients are extremely limited due the highly resistant nature of this cancer. Sarcoma remains a disease with high unmet medical need."

The study will also include use of pharmacodynamic and pharmacogenomic biomarkers, including functional imaging, to assess the effects of AP23573 on the mTOR pathway and to help identify patients who are likely to benefit most from treatment with AP23573.

About Sarcoma

Sarcomas are cancers of the connective tissue, including bones, muscles, fat, cartilage, and joints. Sarcomas can arise anywhere in the body and are divided into two main groups - bone tumors and soft tissue sarcomas. They are further sub-classified based on the type of cell found in the tumor. All sarcomas share certain pathologic characteristics. There are approximately 10,000 new cases of sarcoma diagnosed each year in the United States and close to 40,000 sarcoma patients being treated in the United States and Europe. More information about sarcomas is available on the web at http://www.sarcoma.net/facts.htm and at http://www.sarcomafoundation.com/master.html?Articleld=90.

About AP23573

The small-molecule drug, AP23573, starves cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF).

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD also has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.

Some of the matters discussed herein are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management`s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding the Company`s ability to accurately estimate the actual research and development expenses and other costs associated with the preclinical and clinical development of our product candidates, the adequacy of our capital resources and the availability of additional funding, risks and uncertainties regarding the Company`s ability to successfully conduct preclinical and clinical studies of its product candidates, including those clinical trials noted in this press release, risks and uncertainties that clinical trial results at any phase of development may be adverse or may not be predictive of future result or lead to regulatory approval of any of the Company`s product candidates, and risks and uncertainties relating to regulatory oversight, intellectual property claims, the timing, scope, cost and outcome of legal proceedings, future capital needs, key employees, dependence on the Company`s collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other risks detailed in the Company`s public filings with the Securities and Exchange Commission, including ARIAD`s Annual Report on Form 10-K for the fiscal year ended December 31, 2003. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company`s expectations, except as required by law.

VORBÖRSLICH KNAPP 6% im PLUS

--------------------------------------------------------------------------------
Contact:
ARIAD Pharmaceuticals, Inc.
Tom Pearson, 610-407-9260
or
Kelly Lindenboom, 617-621-2345

[zuzuiop]

endlich gehts zur sache
gewartet haben wir ja lange genug

jetzt noch eine positive meldung bezüglich test´s eines ihrer medikamente und ab geht´s

[1upandaway]

schön langsam wirds wieder interessant hier, wo bleiben die angekündigten deals, was passiert hier hinter den kulissen, sehen wir kurse von über 50 dollar wieder? es wird sicher interessant 2005, hoffe auf 2 stellige Kurse 2005

[1upandaway]

Lehman highlights ARIA with $17 tgt as one of the few co`s in the oncology space to have made significant advances in clinical development since ASCO 2004 and should have significant data at ASCO 2005 to drive investor interest. With 2 phase II trials for mTOR inhibitor AP23573 enrolling rapidly in sarcoma and various hematologic malignancies, firm expects significant data flow from ARIA in 2005 both at ASCO in May and later in the year at EORTC and ASH. Providing upside beyond a trade into ASCO is the potential for favorable resolution to NFKB litigation with LLY over Xigris and Evista, as well as the potential for resurrection of the Src/Abl platform. In addition to ARIA, firm also expects TELK and OSIP to be included in a small ASCA basket.
long and strong

[bernie55]

Press Release Source: ARIAD Pharmaceuticals, Inc.
Thursday January 27, 7:30 am ET
Up to $39 Million in Payments, Plus Royalties on Product Sales


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 27, 2005-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced that it has entered into non-exclusive agreements with Medinol, Ltd., one of the leading cardiovascular medical device companies, to develop and commercialize stents and other medical devices to deliver ARIAD`s mTOR inhibitor, AP23573, to prevent reblockage of injured vessels following stent-assisted angioplasty.
ADVERTISEMENT


ARIAD is eligible to receive license fees and regulatory, clinical and commercial milestones of up to $39.25 million, if two products are developed, plus royalties on worldwide product sales. ARIAD will be responsible for supplying AP23573 to Medinol, and Medinol will be responsible for the development and commercialization of the medical devices delivering AP23573. ARIAD has retained the right to enter into two additional non-exclusive agreements to develop and commercialize AP23573 in drug-delivery devices for vascular disease. Additional terms were not disclosed.

"We are pleased to have one of the most innovative and successful medical device companies as our first partner to develop and commercialize drug-delivery stents incorporating AP23573 - our lead mTOR inhibitor which is in Phase 2 oncology clinical trials," said Harvey J. Berger, M.D., chairman and chief executive of ARIAD. "We believe that Medinol has the design and manufacturing capabilities to develop differentiated stent platforms and polymer formulations that will enable its next-generation stents to achieve substantial penetration in a market that is estimated to grow to over $6 billion by 2008."

Medinol is a leader in stent technology and the inventor, designer, and manufacturer of the NIR® line of stents, including the NIRFLEX(TM) stents. Understanding the need for simultaneous flexibility and support, Medinol created the NIRFLEX stents, which are currently available worldwide for coronary and peripheral use.

Under a 2002 agreement, Medinol and W.L. Gore & Associates, a leading advanced technology company, are collaborating to develop innovative stenting solutions that incorporate key features of their respective technologies (i.e., metal stents, polymer formulations, and advanced delivery systems). Medinol may now utilize ARIAD`s drug, AP23573, with these combined technologies. Gore`s unique technology in the polymer and biocompatible polymer areas should contribute to the design and development of the polymer layer used to control the release of the drug from the stent and to the optimization of the delivery system that will allow easy and safe use of the new system in all desired vascular sites. Medinol`s stents are also marketed and distributed worldwide by Gore.

About Restenosis and Drug-delivery Stents

Restenosis is a reblockage of an artery at the same site where a treatment, such as a balloon angioplasty and/or a stent procedure, has already taken place. In patients who have undergone stent-assisted angioplasty, restenosis within and around the metal stent is likely to occur in approximately 15 to 30% of such patients, depending on the stent design and underlying disease features. The main reason for such reblockage is the overgrowth of tissue (similar to "scar tissue") that may cause narrowing of the vessel and further constriction. Stents that release a medication (e.g., sirolimus or paclitaxel) have been shown to reduce the extent of tissue overgrowth, lower the incidence of reblockage, and result in better clinical outcomes.

About AP23573

The small molecule drug, AP23573, starves cancer cells and shrinks tumors by inhibiting the cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF). AP23573 also blocks the proliferation and migration of vascular smooth muscle cells, the primary cause of narrowing and reblockage of injured arteries, and is an analog of sirolimus, another mTOR inhibitor that has been approved for use on drug-eluting stents. AP23573 is currently in Phase 2 clinical development in patients with solid tumors and hematologic cancers.

About Medinol

Medinol, Ltd. is a global leader in the field of stents and stenting systems with a vast and significant portfolio of intellectual property. Medinol has developed a unique approach to the design and manufacture of an extensive product pipeline. Its new-generation stents reflect the company`s uncompromising commitment to continuous innovation, unique product design and top-quality product. Medinol`s stent technology, with its advantageous features in the uniformity of strut distribution, provides for an optimal drug-delivery platform by increasing the uniformity of drug concentrations in tissues. Medinol, founded in 1992, is privately held and headquartered in Tel Aviv, Israel. Additional information about Medinol can be found on the web at http://www.medinol.com.

About Gore

Gore is a leading manufacturer of thousands of advanced technology products for the electronics, industrial, fabrics and medical markets. The Gore Medical Products Division provides creative healing solutions to complex medical problems. Gore Medical provides such products as synthetic vascular grafts, interventional devices, surgical meshes for hernia repair, and sutures for use in vascular, cardiac, general surgery and orthopedic procedures. With more than 10 million implants, these devices have been saving and improving the quality of lives worldwide for nearly thirty years. Additional information about Gore can be found on the web at www.goremedical.com.

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol, Ltd. also is developing stents and other medical devices that deliver ARIAD`s lead cancer product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.

Some of the matters discussed herein are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management`s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding the Company`s ability to accurately estimate the timing and actual research and development expenses and other costs associated with the preclinical and clinical development and manufacture of our product candidates, the adequacy of our capital resources and the availability of additional funding, risks and uncertainties regarding our ability to manufacture our product candidates on a commercial scale or to supply our product candidates to our collaborator for use in its product candidates, risks and uncertainties regarding our and our collaborator`s ability to successfully enroll and conduct preclinical and clinical studies of product candidates, including our product candidates to treat cancers described in this release and our collaborator`s medical device product candidates to treat vascular disease, risks and uncertainties that clinical trial results at any phase of development including those described in this release may be adverse or may not be predictive of future results or lead to regulatory approval of any of our or our collaborator`s product candidates, risks and uncertainties of third-party intellectual property claims relating to our and our collaborator`s product candidates, and risks and uncertainties relating to regulatory oversight, the timing, scope, cost and outcome of legal proceedings, including litigation concerning our NF-(kappa)B patent portfolio, future capital needs, key employees, dependence on our collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other risks detailed in the Company`s public filings with the Securities and Exchange Commission, including ARIAD`s Annual Report on Form 10-K for the fiscal year ended December 31, 2003. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company`s expectations, except as required by law.

[bernie55]

Thursday January 27, 7:30 am ET
2005 Clinical Development and Financial Guidance to be Provided


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 27, 2005--
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) will hold a live webcast of its quarterly conference call at 8:30 a.m. EST on Tuesday, February 1, 2005. Senior management will discuss fourth quarter and full-year results, as well as provide clinical development and financial guidance for 2005. The Company will announce the highlights of these topics in a press release to be issued before the market opens on Tuesday, February 1, 2005.

[bernie55]

Analysten-Bewertung - 03.02.05


Rating-Update: Die Analysten von Lazard Freres stufen die Aktie von Ariad Pharmaceuticals in einer Ersteinschätzung mit "buy" ein.
Das Kursziel werde bei 11 USD gesehen........

Quelle: Lazard Freres

[zuzuiop]

hey, unser baby fängt ganz gut an zu laufen

[1upandaway]

und wie es laufen wird

[zuzuiop]

die biotechs werden doch endlich wieder mal nach oben gehen oder ?
unsere ariad hat ganz schön verloren die letzte zeit

[zuzuiop]

weiß jemand warum ariad die letzten tage so fällt
gibt es gerüchte ????
danke

[zuzuiop]

da wissen wieder mal einige mehr !!!!!
das gibts ja nicht, nur noch verkäufer

[zuzuiop]

nicht schlecht heute +13 %
wurde aber auch wieder einmal zeit
schätze mal, dass hier wieder ein paar etwas mehr wissen hoffe auf eine meldung in den nächsten tagen

[1upandaway]

fda fast track status kann nur bedeuten das es gute testergebnisse geben wird

[zuzuiop]

ich glaub mal, daß hier jemand schon mehr weiß !!!
am montag sind in kurzen abständen 4 mal über 11.000 stk. gekauft worden
ist ja kein pappenstiel oder ?
heute um 8.30 kommen erst mal die zahlen, dann sehen wir weiter

[zuzuiop]

news !!!!!!!!!!!!!!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that clinical investigators from leading cancer centers will present, for the first time, data from Phase 2 and Phase 1 clinical trials of the Company`s novel mTOR inhibitor, AP23573, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 13 to 17, 2005. Five presentations will highlight new clinical results on AP23573 as a single agent in solid tumors (e.g., soft-tissue and bone sarcomas) and hematologic malignancies (e.g., leukemias and lymphomas), including studies with biomarkers and functional imaging.

"AP23573 recently was designated as a fast-track product for the treatment of soft-tissue and bone sarcomas by the U.S. Food and Drug Administration based, in part, on the agency`s review of our Phase 2 and Phase 1 clinical data. The interim results of our Phase 2 clinical trial in this indication will be presented for the first time at the ASCO meeting," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

The schedule and meeting places for the general poster and poster-discussion sessions, together with the abstract and poster numbers, are listed below:

Sunday, May 15, 2005 at 8:00 a.m. to 12:00 p.m.

Abstract No. 3043; Poster No. J5

"Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), an mTOR inhibitor"

Presenter: Apurva A. Desai, M.D.
Location: Level 2, Hall C

Sunday, May 15, 2005 at 1:00 p.m. to 5:00 p.m.
Abstract No. 9028; Poster No. 15

"Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using (18F)-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan"

Presenter: Kamalesh K. Sankhala, M.D.
Location: Level 2, Hall F4

Monday, May 16, 2005 at 8:00 a.m. to 12:00 p.m.
Abstract No. 9068; Poster No. N13

"A phase 2 study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas"

Presenter: Sant P. Chawla, M.D.
Location: Level 2, Hall C

Monday, May 16, 2005 at 1:00 p.m. to 5:00 p.m.
Abstract No. 3033; Poster No. 20

"Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor"

Presenter: Victor M. Rivera, Ph.D.
Location: Level 3, 314A

Tuesday, May 17, 2005 at 8:00 a.m. to 12:00 p.m.
Abstract No. 6631; Poster No. D8

"A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies"

Presenter: Eric Feldman, M.D.
Location: Level 2, Hall F4

The following abstract will be published in the Proceedings of the American Society of Clinical Oncology:

"PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor" L. Janisch, A. A. Desai, M. Mita, R. Parsons, M. Goldston, H. L. Knowles, C. L. Bedrosian, E. Rowinsky, A. Tolcher, and M. J. Ratain.

About AP23573

The small-molecule drug, AP23573, starves cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF) in tumor and endothelial cells. AP23573 also blocks the proliferation and migration of vascular smooth muscle cells, the primary cause of narrowing and reblockage of injured arteries, and is an analog of sirolimus, another mTOR inhibitor that has been approved for use in drug-eluting stents. AP23573 is currently in Phase 1 and 2 clinical trials in patients with solid tumors and hematologic cancers. AP23573 has been designated a fast-track product by the U.S. Food and Drug Administration for the treatment of soft tissue and bone sarcomas.

[bernie55]

UPGRADES & DOWNGRADES HISTORY 2005:


28-Jun-05 Oppenheimer Buy

27-Jun-05 Bear Stearns Outperform

14-Apr-05 Adams Harkness Buy

2-Feb-05 Lazard Freres Buy


Grüße, bernie55

[bernie55]

ARIAD Initiates Phase 2 Clinical Trial of AP23573 in Patients with Recurrent or Persistent Endometrial Cancer; Over 40,000 new cases of endometrial cancer expected in 2005


CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 30, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced initiation of enrollment of patients with recurrent or persistent endometrial cancer in a global Phase 2 clinical trial of its novel mTOR inhibitor, AP23573, as a single agent. Endometrial cancer is the most common gynecologic malignancy, including ovarian cancer.

This non-randomized study will evaluate the clinical benefit of AP23573 in well-characterized endometrial cancer patients. Up to approximately 45 patients will be enrolled in the trial at several centers in the United States and Europe. AP23573 will be administered intravenously using a daily dosing regimen. Patients will be followed for at least six months after enrollment but may continue on AP23573 if they have clinical benefit. Data on multiple mTOR-pathway biomarkers, including functional imaging in a subset of patients, will be obtained to help identify patients who are most likely to benefit from treatment with AP23573.

"Biological and genetic studies of mTOR-pathway activation in endometrial cancer highlight the importance of this pathway in these tumors and the potential for increased sensitivity to mTOR inhibition. These data led us to include endometrial cancer as another potential indication with substantial unmet medical need that warrants further study with AP23573 in Phase 2 trials," said Tim Clackson, Ph.D., chief scientific officer and senior vice president of ARIAD.

About Endometrial Cancer

It is expected that over 40,000 new cases of endometrial cancer will be diagnosed in the U.S. in 2005, and over 7,000 deaths will occur. Endometrial cancer, which develops from the inner lining of the uterus is the most common cancer in the female reproductive system. Prognosis for patients is primarily based on the time of diagnosis relative to the stage of the cancer. Initial treatment consists of surgery, alone or in combination with radiation, or hormonal therapy. For those women with disease progression, chemotherapy is the only currently available treatment option, and limited benefit has been seen in such cases, emphasizing the need for new molecularly targeted therapies.

About AP23573

ARIAD`s small-molecule drug, AP23573, starves cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR, which regulates the response of tumor cells to nutrients and growth factors, and controls tumor blood supply and angiogenesis through effects on Vascular Endothelial Growth Factor (VEGF) in tumor and endothelial cells. AP23573 also blocks the proliferation and migration of vascular smooth muscle cells, the primary cause of narrowing and reblockage of injured arteries, and is an analog of sirolimus, another mTOR inhibitor that has been approved for use in drug-eluting stents. AP23573 is currently in Phase 1 and 2 clinical trials in patients with solid tumors and hematologic cancers. AP23573 has been designated a fast-track product by the U.S. Food and Drug Administration for the treatment of soft-tissue and bone sarcomas.

CONTACT: ARIAD Pharmaceuticals, Inc.Edward Fitzgerald (Investors)
617-621-2345
or
Pure Communications
Andrea Johnston (Media)
910-681-1088

SOURCE: ARIAD Pharmaceuticals, Inc.

[bernie55]

Jobs Data, Earnings & Analysts Boost Equity Futures

Stocks are poised to open higher after the Dept. of Labor reported the nation added 146K new nonfarm jobs in June and the unemployment rate fell to a multi-year low of 5.0%. Semiconductors (SMH) are indicated higher.
UBS named INTC, TXN & IRF their top picks. Potential movers in the drug sector: BAC started coverage of HGSI, INCY, IMCL, EXEL, OSIP and ARIA at Buy .

VRTX, ABGX, MLNM, ZGEN and ONXX were initiated at Neutral. AA & ACN should gap higher on their positive earnings reports. Jefferies maintained its Neutral rating on the Specialty Retail sector.

[bernie55]

7,15 US-Dollar +0,55

+8,33 %

[bernie55]

7,80 US Dollar +0,39

+5,26 %

...mannomann.....Ariad läuft und läuft....vielleicht kommen ja bald News ........

[bernie55]

ARIAD to Webcast Presentation at the Adams Harkness 25th Annual Summer Seminar in Boston


CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 26, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that its presentation at the Adams Harkness 25th Annual Summer Seminar at the Marriot Long Wharf Hotel in Boston, Massachusetts, on Tuesday, August 2, 2005 will be webcast live and can be accessed by visiting the investor relations section of the Company`s website at http://www.ariad.com/investor.

The presentation will be given at 11:30 a.m. (ET) by Timothy P. Clackson, Ph.D., chief scientific officer of ARIAD, who will provide an overview of the Company and its progress in key programs. A replay will be available on the ARIAD website approximately three hours after the presentation and will be archived for two weeks.

[bernie55]

ARIAD To Webcast Presentation at the Bear Stearns 18th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 6, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced that its presentation at the Bear Stearns 18th Annual Healthcare Conference at the Grand Hyatt Hotel in New York, New York, on Monday, September 12, 2005 will be webcast live and can be accessed by visiting the investor relations section of the Company`s website at http://www.ariad.com/investor.
ADVERTISEMENT
The presentation will be given at 8:30 a.m. (ET) by Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, who will provide an overview of the Company and its progress in key programs. A replay will be available on the ARIAD website approximately three hours after the presentation and will be archived for two weeks.